Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers
Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose
Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor
agonist HSK21542 in Healthy Volunteers.
The study will enroll approximately 50 adults. The anticipated study duration will be up to 6
months.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.